Company News Summary | 06 May 2021

Click the print icon in your browser to print this report. Currency is in AUD unless otherwise specified

CSL Provides an Update on Agreement with uniQure

14:17:00 | Associate analysts

Original annuncemenet:Update on CSL Agreement with uniQure

CSL provided an update stating that the company announced the closing of the company's global commercialisation and license agreement with uniQure for etranacogene dezaparvovec (AMT-061), a novel gene therapy for the treatment of haemophilia B. The company stated that the global licensing agreement was announced on 24 June 2020 and the closing follows the completion of antitrust reviews of the transaction in the US, the UK and Australia. The company also reported that under the terms of the agreement, uniQure will receive an cash payment of US$450 million by 13 May, 2021.

This report appeared on 2021 Morningstar Australasia Pty Limited

© Copyright 2021 Morningstar Australasia Pty Ltd ABN: 95 090 665 544 ("Morningstar"), AFSL no 240892. (a subsidiary of Morningstar, Inc.). This information is to be used for personal, non-commercial purposes only. No reproduction is permitted without the prior written content of Morningstar. Some of the material provided is published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO").

DISCLAIMER: To the extent that any of the content above constitutes advice, it is general advice that has been prepared without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain appropriate financial, legal and taxation advice before making any financial investment decision. If applicable, investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Please refer to our Financial Services Guide (FSG) for more information at FSG or phone Morningstar on 1800 03 44 55 to request a copy. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for any use or distribution of any of this information

DISCLOSURE: Employees may have an interest in the securities discussed in this report.